HematologyNews.net

Hematology Xagena

XagenaNewsletter
Medical Meeting
Xagena Mappa
Pneumobase.it

Weekly Selinexor, Bortezomib, and Dexamethasone versus twice weekly Bortezomib and Dexamethasone in patients with multiple myeloma after one to three prior therapies: initial results of the phase III BOSTON study


Selinexor ( Xpovio ) is an oral, selective inhibitor of XPO1-mediated nuclear export, leading to the reactivation of tumor suppressor proteins.

In a phase 1b/2 study, the combination of once weekly ( QW ) Selinexor with Bortezomib and Dexamethasone ( SVd ) was well tolerated with anti-multiple myeloma activity in patients with proteasome inhibitor ( PI )-sensitive and PI-refractory disease.
While twice weekly ( BIW ) Bortezomib in combination therapy is efficacious, prolonged use is limited due to peripheral neuropathy ( 50-60% ).

The BOSTON study was designed to determine if SVd regimen improves progression free survival ( PFS ), overall response rates ( ORR ) and reduces the rate of peripheral neuropathy versus Vd regimen.

BOSTON is a global, phase 3, randomized study of QW SVd versus BIW Vd after 1-3 prior anti-multiple myeloma regimens.

The primary endpoint is progression-free survival. Secondary endpoints include overall response rates, overall survival ( OS ) and peripheral neuropathy ( rates and EORTC QLQ-CIPN20 outcomes ).

Randomization was stratified by treatment with prior therapies with proteasome inhibitors, number of prior anti-multiple myeloma regimens, and Revised International Staging System ( R-ISS; stage III vs I or II ).

Following confirmation of progressive disease, patients on Vd regimen could cross over to either: 1) SVd for patients able to tolerate continued Bortezomib or 2) Selinexor and Dexamethasone for patients with Bortezomib intolerance.

402 patients were enrolled; 195 and 207 to SVd and Vd, respectively. Median age was 67 ( range: 38-90 ). Most ( 59.6% ) patients were 65 years and 57.1% were male.
R-ISS stage at the time of multiple myeloma diagnosis was III for 18.5% of patients.
Baseline characteristics were balanced across the two arms.

SVd regimen has significantly prolonged progression-free survival versus Vd regimen ( median 13.93 vs 9.46 months, HR = 0.70, P = 0.0066 ).

SVd regimen is associated with a significantly higher overall response rates ( 76.4% vs 62.3%, P = 0.0012) .

Median overall survival was not reached on SVd regimen versus 25 months on Vd regimen ( P = 0.28 ).

Most frequent treatment-related adverse events ( grade 3 ) for SVd vs Vd were thrombocytopenia ( 35.9% vs 15.2% ), fatigue ( 11.3% vs 0.5% ) and nausea ( 7.7% vs 0% ). Clinically important differences were reported on the motor, autonomic and sensory scales on CIPN20. Peripheral neuropathy rates ( grade 2 ) were significantly lower with SVd vs Vd ( 21.0% vs 34.3%, P = 0.0013 ).

In conclusion, BOSTON is the first phase 3 study to evaluate the clinical benefit of SVd for relapsed / refractory multiple myeloma. T
he study met the primary endpoint: once weekly SVd regimen has significantly improved progression-free survival and overall response rates compared to twice weekly Vd regimen.
Rates of peripheral neuropathy were significantly reduced with numerically fewer deaths on SVd regimen versus Vd regimen.( Xagena )

Source: American Society of Clinical Oncology ( ASCO ) Virtual Meeting, 2020

XagenaMedicine_2020



Indietro